Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Eledon Pharmaceuticals (ELDN) Equity Average (2016 - 2026)

Eledon Pharmaceuticals filings provide 4 years of Equity Average readings, the most recent being $20.0 million for Q4 2017.

  • On a quarterly basis, Equity Average rose 45.42% to $20.0 million in Q4 2017 year-over-year; TTM through Dec 2017 was $20.0 million, a 45.42% increase, with the full-year FY2017 number at $8.4 million, up 20837.5% from a year prior.
  • Equity Average hit $20.0 million in Q4 2017 for Eledon Pharmaceuticals, down from $22.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $102.6 million in Q4 2014 to a low of $10.3 million in Q1 2017.
  • Median Equity Average over the past 4 years was $34.6 million (2016), compared with a mean of $46.0 million.
  • Biggest five-year swings in Equity Average: tumbled 72.12% in 2016 and later skyrocketed 45.42% in 2017.
  • Eledon Pharmaceuticals' Equity Average stood at $102.6 million in 2014, then tumbled by 63.59% to $37.3 million in 2015, then crashed by 63.1% to $13.8 million in 2016, then surged by 45.42% to $20.0 million in 2017.
  • The last three reported values for Equity Average were $20.0 million (Q4 2017), $22.0 million (Q3 2017), and $23.4 million (Q2 2017) per Business Quant data.